NASDAQ:CRVS

Corvus Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CRVS

*Your capital is at risk

$11.60

-0.0900 (-0.770%)

At Close: Jun 03, 2026

Corvus Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -41.27. In total, the insiders bought 25.42M and sold 10.9M CRVS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-41.27
● Buy	25.42M shares
● Sell	10.9M shares
90% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence May 18, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -41.27. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (90% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Grais Linda Director	Director	15 000 Value: $63.6K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Clark Ian T Director	Director	15 000 Value: $63.6K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Morrison Scott W Director	Director	15 000 Value: $63.6K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Thompson Peter A.	Director	15 000 Value: $63.6K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Thompson Peter A.	Director	15 000 Value: $63.6K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Morrison Scott W Director	Director	15 000 Value: $63.6K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Clark Ian T Director	Director	15 000 Value: $63.6K
Jun 12, 2025 Buy	Stock Option (Right to Buy) A-Award	Grais Linda Director	Director	15 000 Value: $63.6K
Jun 04, 2025 Buy	Common Stock M-Exempt	Jones William Benton See Remarks	Officer	19 357 Value: $67.7K
Jun 04, 2025 Buy	Warrant (Right to Buy) M-Exempt	Jones William Benton See Remarks	Officer	19 357 Value: $67.7K
Jun 04, 2025 Buy	Warrant (Right to Buy) M-Exempt	Jones William Benton See Remarks	Officer	19 357 Value: $67.7K
Jun 04, 2025 Buy	Common Stock M-Exempt	Jones William Benton See Remarks	Officer	19 357 Value: $67.7K
May 07, 2025 Buy	Common Stock M-Exempt	Miller Richard A Md President And CEO	CEO / President	559 073 Value: $1.96M
May 07, 2025 Buy	Warrant (Right to Buy) M-Exempt	Miller Richard A Md President And CEO	CEO / President	559 073 Value: $1.96M
May 07, 2025 Buy	Warrant (Right to Buy) M-Exempt	Miller Richard A Md President And CEO	CEO / President	559 073 Value: $1.96M
May 07, 2025 Buy	Common Stock M-Exempt	Miller Richard A Md President And CEO	CEO / President	559 073 Value: $1.96M
Apr 08, 2025 Buy	Stock Option (Right to Buy) A-Award	Van Den Broek Richard Director	Director	30 000 Value: $84.6K
Apr 08, 2025 Buy	Common Stock	Van Den Broek Richard Director	Director	0 Value: $0
Apr 08, 2025 Buy	Common Stock	Van Den Broek Richard Director	Director	0 Value: $0
Apr 08, 2025 Buy	Stock Option (Right to Buy) A-Award	Van Den Broek Richard Director	Director	30 000 Value: $84.6K
Dec 20, 2024 Buy	Stock Option (Right to Buy) A-Award	Arcara Jeffrey Chief Business Officer	Officer	50 000 Value: $249.5K
Dec 20, 2024 Buy	Stock Option (Right to Buy) A-Award	Jones William Benton See Remarks	Officer	300 000 Value: $1.50M
Dec 20, 2024 Buy	Stock Option (Right to Buy) A-Award	Lea Leiv Chief Financial Officer	C-Suite Officer	300 000 Value: $1.50M
Dec 20, 2024 Buy	Stock Option (Right to Buy) A-Award	Miller Richard A Md President And CEO	CEO / President	750 000 Value: $3.74M
Dec 20, 2024 Buy	Stock Option (Right to Buy) A-Award	Miller Richard A Md President And CEO	CEO / President	750 000 Value: $3.74M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CORVUS PHARMACEUTICALS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat pa...

Read Full Profile Here